inovio pharmaceuticals, inc. corporate presentation december 2013

Revolutionizing Vaccines

Dr. J. Joseph Kim President & CEO NYSE MKT: INO

Forward Looking Statement

Our commentary and responses to your questions may contain forward-looking statements, including comments concerning clinical trials and product development programs, evaluation of potential opportunities, the level of corporate expenditures, the assessment of Inovio’s technology by potential corporate partners, capital market conditions, timing of events, cash consumption and other subjects. Information concerning factors that could cause actual results to differ materially from those set forth in our Annual Report on Form 10-K for the year ended December 31, 2012, our Form 10-Q for the quarter ended September 30, 2013 and other regulatory filings from time to time.

2

Roche Partnership

3

• Collaborating with a global leader in innovative cancer drugs • Develop and commercialize Inovio’s prostate cancer (INO-

5150) and hepatitis B (INO-1800) immunotherapies • $10 million up-front payment • $412.5 million milestone payments for development and

commercial events • Roche may pay other development milestone payments if it

pursues other indications with INO-5150 or INO-1800 • Roche to fund all ongoing development costs • Up to double-digit royalties on sales of a marketed product

• Are safe and tolerable

• Requires a directive to attack

T cells: Inovio Commands the Body’s SWAT Team

T cell Cytotoxic T lymphocyte

Infected cell

Provided by Dr. Philip Greenberg Hutchinson Cancer Research Center

4

Inovio’s Technology

Plasmids

Electroporation device

• Synthetic DNA vaccines

• Electroporation delivery

• Best-in-class immune responses

• Favorable safety profile • Over 400 patents

Inovio’s Technology

5

Choose important strains/variants of target virus/cancer

Select important common antigen(s), which body recognizes as foreign and relates to a cancer or infected cell

The Basis For How We Stimulate T-cells

Strain 1

Strain 2

Strain X

Antigen Y

Antigen Y

Antigen Y

6

Strain 1

Strain X

Strain 2

Antigen Y

Antigen Y Antigen Y


7

Identify gene sequence of selected antigen(s) from chosen strains/variants of the virus/cancer

Synthetically create optimal consensus gene sequence for the selected antigen

Insert SynCon® gene sequence for selected antigen into DNA plasmid

SYNCON® DNA

Antigen consensus

sequence

DNA Plasmid


8

SynCon DNA plasmid ready to manufacture

DNA vaccine delivered into muscle or skin

Electroporation: millisecond electrical fields applied

Temporary pores in cell membrane; significant cellular uptake of vaccine

Antigen-presenting cells engulf the antigens and carry them to lymph nodes

Antibodies or killer T-cells that can eliminate cancerous or infected cells are produced

Cell membrane reseals. Cellular machinery uses the DNA code to produce one or more of the targeted disease antigens


9

Better Delivery = Enhanced Gene Expression

Ref: Sardesai & Weiner Curr. Opin. Immunol. 2011

1000x enhancement in cellular uptake > 10-100x enhancement in immunogenicity

Intramuscular Intradermal

10

#1 in Accelerating and Driving T Cell Responses

“Immunotherapy against HPV 16/18 generates potent TH1 and cytotoxic cellular immune responses” October 10, 2012

“Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid Interleukin 12 and impact of intramuscular electroporation for delivery” July 8, 2013

11

Broad Medical and Market Opportunities

Product Name

INTERNALLY FUNDED

Indication Preclinical Phase I Phase II

Cervical dysplasia Vgx-3100

Prostate cancer Ino-5150

Breast/lung cancers Ino-1400

EXTERNALLY FUNDED

hiv pennvax®

influenza Ino-3510

Hepatitis C Ino-8000

Hepatitis B ino-1800

malaria MaV-12

Phase III

Therapeutic

Therapeutic

Therapeutic

Therapeutic

Preventive

Preventive

Preventive/Therapeutic

Therapeutic

12

Therapeutic

Therapeutic

Cervical Cancer

Head & Neck Cancer

INO-3112

INO-3112

Inovio’s Lead Program

VGX 3100: • Capitalizes on Inovio’s ability to generate T cells • Immunotherapy for pre-cancers and cancers

caused by human papillomavirus (HPV) • Phase II on-going: high grade cervical pre-

cancers (CIN 2/3 dysplasia) • Projected efficacy data: mid-2014

13


14

VGX-3100: Phase I Study Data

• Strong T-cell response in 14 of 18 (78%) vaccinated subjects at month 4

• 83% response rate in highest dose group

*Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med. 2012 Oct; 4:155ra13. dOI:10.1126/scitranslmed.3004414


15

Phase I trial results for vgx-3100

• 9 month durability of robust T cell response in 12/14 responders

• Safe & well tolerated


Source: Science Translational Medicine Oct. 2012 16

• 10/11 responders showed killing effect against target cells

17


Broad Medical and Market Opportunities

HPV product franchise planning • CIN 2/3 Phase III • Other HPV-related indications: initiate Phase IIs • Orphan designation potential

18

Strategy

• Build on proof-of-concept studies with phase I/II clinical trials

• Spread cost/risk with: o Non-dilutive

partner funding o R&D grants

o “Sponsored”

clinical trials • May partner or license

out products for further development and commercialization

19

Broad Base of Support for Inovio

• Universities • Government • Foundations • Corporate partnerships

20

Almost $60M in funding since 2009

21

Broad Base of Support for Inovio

power of our people

• Management • Board of Directors • Scientific Advisory Board

22

anthrax Louis Pasteur

Peter Kies CFO • Ernst & Young • Experience with growth companies

Mark L. Bagarazzi, MD CMO • Clinical research experience incl. Merck • Led clinical/regulatory for shingles and rotavirus vaccines; DNA vaccine expert

23

J.Joseph Kim, PhD President & CEO

• Decades of biotechnology/pharma management

• Merck: hepatitis A and B vaccines manufacturing; HIV vaccine (Ad5) R&D

Niranjan Y. Sardesai, PhD COO

• Extensive biotech management and product development experience

• Led development of diagnostics for mesothelioma, bladder cancer, and ovarian

cancer for Fujirebio Diagnostics

Management


J.Joseph Kim, PhD • President & CEO, Inovio

Adel Mahmoud, PhD • Professor, Princeton University • Former President, Merck Vaccines • Responsible for Gardasil®, Zostavax®, Proquad® and Rotateq®

Morton Collins, PhD • General Partner, Battelle Ventures and Innovations Valley Partners

24

Simon X. Benito • Former Senior Vice President,

Merck Vaccine Division

Angel Cabrera, PhD • President, George Mason University

• Former President, Thunderbird School of Global Management

Avtar Dhillon, MD Chairman, BOD

• Former President & CEO, Inovio Biomedical

Board of Directors


Stanley A. Plotkin, MD • Developed rubella and rabies vaccines • Oversaw Sanofi flu vaccine • Emeritus Professor, Wistar Institute & University of Pennsylvania

Philip Greenberg, MD • Expert in T-cell immunology • Head, Immunology Program, Fred Hutchinson Cancer Research Center

25

Thomas S. Edgington, MD • Founded multiple biotech companies;

extensively published • Emeritus Professor, Scripps

Research Institute

Anthony W. Ford-Hutchinson, PhD • Former SVP, Vaccines R&D, Merck

• Oversaw development: Singulair®, Januvia®, Gardasil®, Zostavax®, Proquad® and Rotateq®

David B. Weiner, PhD Chairman

•“Father of DNA vaccines” • Dept. of Pathology & Laboratory Medicine,

University of Pennsylvania

Scientific Advisory Board

26 1/1/13 2/1/13 3/1/13 4/1/13 5/1/13 6/1/13 7/1/13 8/1/13 9/1/13 10/1/13 11/1/13 12/1/13

Stock Price $3.00

$0.50

Financial Information

Cash, cash equivalents & short-term investments1 $ 46.3 M

Debt1 0 M

Cash runway 1Q 2016

Issued & outstanding shares2 208.4 M

Recent price3 $1.98

Market cap3 $412.6 M

NYSE MKT: INO

1Sep. 30, 2013 3 Dec. 9, 2013

27

11/9/2013 12/9/2013

Additional cash raised2

$ 11.1 M

2Nov. 12, 2013

$1.98

Upcoming Value Drivers

28

INTERNALLY FUNDED EXTERNALLY FUNDED

Ino-5150 1H 2014 Initiate phase I/IIa Prostate cancer

Vgx-3100 Mid-2014 Phase II study data Cervical dysplasia

INO-3112 1H 2014 Initiate phase I/IIa

Head & Neck Cancer

29


INO-3112 1H 2014 Initiate phase I/IIa

Cervical Cancer

Ino-1400 2014 Initiate phase I/IIa

Breast/lung Cancer

INTERNALLY FUNDED EXTERNALLY FUNDED

PennVAX® 1H 2014 Initiate PENNVAX -GP phase I study HIV

Ino-8000 2015 Report phase I data Hepatitis C

MAV-12 2014 Initiate phase I/IIa

Malaria

30


Ino-1800 2014 Prepare phase I/IIa Hepatitis B

Investor Highlights • Break-through immune therapy with the power to save lives and maximize shareholder value

• Targeting broad range of diseases and billion dollar markets • Best-in-class T cells to prevent, treat & cure cancers and infectious diseases

• Phase II efficacy data coming

• Validating partnership with Roche

The Opportunity

31

Bernie Hertel Senior Director, Corporate Communications 858-410-3101 [email protected]

Investor Contact

investor contacts

32

inovio pharmaceuticals, inc. corporate presentation december 2013

Business